Collaboration to pair artificial intelligence proficiencies with clinical research expertise.
Parexel, a contract research organization (CRO), and Partex, a data-to-drugs pharma platform, have inked a deal aiming to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for biopharmaceutical customers worldwide and de-risk the assets in their portfolios. Under the partnership, Partex’s clinical trial execution will be ran by Parexel as the preferred CRO provider. The organizations will also work together to improve customer clinical trial execution through the Partex-validated AI platform.
"One of the biggest and most complex challenges in drug development is anticipating the investigational therapies that will be safe and effective treatment options,” said Jamie Macdonald, CEO, Parexel, in a company press release. “Our innovative alliance with Partex helps to address this challenge by bringing to the forefront those assets with the strongest probability of clinical success, in turn enabling customers to focus their time and resources where it is most beneficial to patients.”
Reference: Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development. Parexel. August 15, 2023. Accessed September 5, 2023. https://newsroom.parexel.com/news-releases/news-release-details/parexel-and-partex-announce-innovative-alliance-leveraging?utm_campaign=PostBeyond&utm_source=LinkedIn&utm_medium=449887&utm_term=Parexel+and+Partex+Announce+Innovative+Alliance+Leveraging+Artificial+Intelligence+and+Big+Data+to+Accelerate+Drug+Discovery+and+Development+%7C+Parexel+International+Corporation